REFRACTORY HODGKIN LYMPHOMA
Clinical trials for REFRACTORY HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy tested for tough-to-treat hodgkin lymphoma
Disease control CompletedThis study tested a combination of a targeted cancer drug (brentuximab vedotin) with three standard chemotherapy drugs for patients whose Hodgkin lymphoma had returned or wasn't responding to treatment. The goal was to find the safest, most effective dose and see how well this co…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New drug tested for patients with Tough-to-Treat blood cancers
Disease control CompletedThis early-stage trial tested the safety and best dose of an investigational drug called flotetuzumab. It involved 13 adults with advanced blood cancers that had returned or stopped responding to standard treatments. The main goal was to understand the drug's side effects and see…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New hope for toughest lymphomas: experimental combo targets Cancer's repair system
Disease control CompletedThis early-stage study tested a new combination of drugs for patients with aggressive lymphomas that have come back or not responded to standard treatments. The main goal was to find the safest dose of a drug called olaparib when given with a powerful chemotherapy regimen before …
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC